Skip to main content
. Author manuscript; available in PMC: 2014 Jan 29.
Published in final edited form as: Addict Biol. 2011 Feb 11;17(2):224–234. doi: 10.1111/j.1369-1600.2010.00295.x

Figure 2. Increased delta opioid receptor (DOP-R)-stimulated [35S]GTPγS binding in the midbrain of yohimbine-treated rats is inhibited by SoRI-9409.

Figure 2

(A) DOP-R-mediated [35S]GTPγS stimulation by the DOP-R agonist, TAN67, is higher in midbrain membranes prepared from rats administered SoRI-9409-vehicle prior to yohimbine compared to midbrain membranes prepared from rats given SoRI-9409-vehicle prior to yohimbine-vehicle. (B) SoRI-9409 inhibits TAN67-stimulated [35S]GTPγS DOP-R binding in midbrain membranes prepared from rats administered SoRI-9409-vehicle prior to yohimbine. Rats were pretreated with SoRI-9409 (5 mg/kg, I.P.) or its vehicle 30 min before yohimbine (2 mg/kg I.P.) or its vehicle. Yohimbine (or vehicle) was administered 30 min before rat brains were collected (n=3 per group, each in triplicate). The values are expressed as mean ± SEM percentage increase in basal [35S]GTPγS binding.